Windtree will coordinate production through a third-party manufacturer while Evofem retains ownership of PHEXXI and continues its commercialization efforts in the U.S. and global markets.

Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that members of its management team will present at the upcoming ...

PHEXXI annual revenues have grown to more than $19 million with more than 96,000 boxes of 12 pre-filled applicators sold in full year 2024. Windtree has manufacturing contacts that we believe are ...

Evofem expects PHEXXI COGS will decrease by 55% to 60% from current levels. Furthermore, there will be no cost to Evofem for the tech transfer to the new manufacturer engaged by Windtree.

Windtree entered into a license and supply agreement with Evofem. The goal of the agreement is reduce the cost of Evofem's PHEXXI by having Windtree contract with the manufacturer. Feel unsure ...

1) The vast majority of 2024 net sales were contributed by PHEXXI® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, Evofem's hormone-free, on demand contraceptive. Sales and ...

31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (EVFM) (OTCQB ...

The product is a first-in-class hormone-free, on-demand prescription contraceptive vaginal gel that women control. PHEXXI annual revenues have grown to more than $19 million with more than 96,000 ...